LUPIN LTD.

Lupin Limited announced the appointment of Mr. Brian Savage as Senior Management Personnel, designated as President, Chief Legal Officer, effective October 22, 2026. Mr. Savage will be responsible for overseeing the company's Global Legal, Compliance, and IP functions. He brings extensive legal leadership experience from the global pharmaceutical industry, including previous roles at Teva Pharmaceuticals and Dechert LLP. His expertise includes legal and regulatory matters, litigation management, and strategic business partnering.

Lupin Ltd has announced that its Board of Directors will convene on November 3, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. In line with SEBI regulations, the company has also informed about the closure of the trading window for designated persons and their relatives from October 1, 2026, until 48 hours after the results declaration. The trading window is set to reopen on November 6, 2026.

Lupin Ltd has received an ESG Rating of '70' for FY26 from NSE Sustainability Ratings and Analytics Limited, a marginal decrease from its FY25 rating of '71'. The company stated that the decline is primarily due to a one-point reduction in both its Social and Governance scores. Notably, NSE Sustainability independently prepared this rating using publicly available information, and Lupin did not engage them for the assessment. This independent rating provides an external perspective on Lupin's environmental, social, and governance performance.

Lupin Limited has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-dose Prefilled Syringe. This approval signifies that Lupin's product is bioequivalent to the reference listed drug and is indicated for treating and preventing hypoprothrombinemia. The U.S. market for this product had estimated annual sales of USD 52.3 million as of August 2026. This approval is a significant step for Lupin in expanding its presence in the U.S. pharmaceutical market.

Lupin Limited has launched Formoflo-G® MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India. This launch follows approval from the Drug Controller General of India (DCGI) and marks a significant advancement in respiratory care. Formoflo-G® combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate for the long-term management of moderate to severe COPD. The product is designed for twice-daily use and aims to provide a more accessible and effective treatment option for the over 55 million people living with COPD in India. Lupin, already a strong player in the respiratory segment, aims to improve patient outcomes with this innovative therapy.

Lupin Ltd announced that its step-down subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), has successfully completed the buyback of 30,559 shares. This transaction, effective October 1, 2026, makes MPPI a wholly owned subsidiary of Nanomi B.V. (a wholly owned subsidiary of Lupin) and consequently, a step-down wholly owned subsidiary of Lupin Ltd. This move consolidates Lupin's control over its Philippine operations.

Lupin Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from October 01, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the board meeting to consider these financial results will be communicated later. This measure is standard practice to prevent potential insider trading ahead of financial disclosures.

Lupin Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL, developed via the 505(b)(2) pathway. This oral liquid formulation is an alternative administration option for adult patients requiring anticoagulation therapy, particularly those who have difficulty swallowing tablets. The active ingredient is apixaban, the same as in Eliquis® by Bristol Myers Squibb. Upon final approval, the product will be manufactured at Lupin's Somerset, New Jersey facility. This development aligns with Lupin's strategy to focus on differentiated medicines addressing patient needs and expanding its therapeutic portfolio.

Global pharmaceutical major Lupin Limited has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg. The approved tablets are bioequivalent to Provigil® Tablets and are indicated for improving wakefulness in adult patients with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). The U.S. market for Modafinil Tablets had estimated annual sales of USD 70.7 million as of July 2026.

Lupin Ltd. has been assigned an ESG Rating of 'Crisil ESG 69' and a Core ESG Rating of 'Crisil Core ESG 65' for FY26 by Crisil ESG Ratings & Analytics Ltd. This places the company in the 'Strong' category. Notably, Crisil ESG Ratings independently prepared this report using publicly available information, without any engagement from Lupin Ltd. The ratings reflect the company's performance in Environmental, Social, and Governance aspects.